Literature DB >> 19822693

Sample size recalculation in sequential diagnostic trials.

Liansheng Larry Tang1, Aiyi Liu.   

Abstract

Before a comparative diagnostic trial is carried out, maximum sample sizes for the diseased group and the nondiseased group need to be obtained to achieve a nominal power to detect a meaningful difference in diagnostic accuracy. Sample size calculation depends on the variance of the statistic of interest, which is the difference between receiver operating characteristic summary measures of 2 medical diagnostic tests. To obtain an appropriate value for the variance, one often has to assume an arbitrary parametric model and the associated parameter values for the 2 groups of subjects under 2 tests to be compared. It becomes more tedious to do so when the same subject undergoes 2 different tests because the correlation is then involved in modeling the test outcomes. The calculated variance based on incorrectly specified parametric models may be smaller than the true one, which will subsequently result in smaller maximum sample sizes, leaving the study underpowered. In this paper, we develop a nonparametric adaptive method for comparative diagnostic trials to update the sample sizes using interim data, while allowing early stopping during interim analyses. We show that the proposed method maintains the nominal power and type I error rate through theoretical proofs and simulation studies.

Mesh:

Substances:

Year:  2009        PMID: 19822693      PMCID: PMC2800369          DOI: 10.1093/biostatistics/kxp044

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  9 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

2.  Sample size determination for group sequential clinical trials with immediate response.

Authors:  K Kim; D L Demets
Journal:  Stat Med       Date:  1992-07       Impact factor: 2.373

3.  Two-stage sample size re-estimation based on a nuisance parameter: a review.

Authors:  Michael A Proschan
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

4.  Frequentist evaluation of group sequential clinical trial designs.

Authors:  Scott S Emerson; John M Kittelson; Daniel L Gillen
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

5.  An adaptive approach to designing comparative diagnostic accuracy studies.

Authors:  Chengqing Wu; Aiyi Liu; Kai F Yu
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

6.  Nonparametric and semiparametric group sequential methods for comparing accuracy of diagnostic tests.

Authors:  Liansheng Tang; Scott S Emerson; Xiao-Hua Zhou
Journal:  Biometrics       Date:  2008-03-27       Impact factor: 2.571

7.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

8.  Group sequential design for comparative diagnostic accuracy studies.

Authors:  Madhu Mazumdar; Aiyi Liu
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

9.  Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.

Authors:  Margaret S Pepe; Ziding Feng; Holly Janes; Patrick M Bossuyt; John D Potter
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

  9 in total
  2 in total

1.  Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling.

Authors:  Joseph S Koopmeiners; Ziding Feng
Journal:  Ann Stat       Date:  2011       Impact factor: 4.028

2.  Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.

Authors:  Joseph S Koopmeiners; Ziding Feng
Journal:  Stat Med       Date:  2015-11-04       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.